Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2016

View Archived Issues

Inovio Pharmaceutical's DNA Zika virus vaccine induces robust immune responses in vivo

Corvidia Therapeutics raises Series A financing, licenses lead compound from AstraZeneca

Genedrive HCV test completes successful external assessment and gets ready for clinical testing

Beloranib achieves primary efficacy endpoint in phase IIb study in patients with severe obesity

Ironwood reports phase Ia data on soluble sGC stimulator IW-1701

Pliant Therapeutics launches with focus on fibrotic disorders

Diabetes drug pioglitazone as potential preventive therapy for recurring strokes

EZH2 inhibition exhibits in vitro and in vivo antitumor activity

Curegenix initiates phase I study of CGX-1321 in advanced solid tumors

Kasuma Partners patents PCSK9 inhibitors

Brilique 60 mg approved in E.U. for patients with history of heart attack

Bayer Schering Pharma describes ATR kinase inhibitors

Merck & Co. discloses FFAR1 agonists

Novartis reports protein kinase C inhibitors

Janssen Pharmaceutica develops mGlu2 receptor modulators

European Commission approves Zurampic for hyperuricemia in gout

Ipsen acquires rights for novel radiopharmaceuticals in oncology

FDA grants breakthrough therapy designation to PKC-412 for newly diagnosed FLT3-mutated AML

Fujifilm initiates phase I trial of FF-10502 for solid tumors, advances other cancer programs

CHLA and Thermo Fisher Scientific to develop NGS-based panel for pediatric cancer research

Temcell set to launch in Japan

Nuvo Research to split into Nuvo Pharmaceuticals and Crescita Therapeutics

FDA accepts for review sNDA for Teflaro in pediatric population

FDA grants fast track designation to Nivalis's N-91115 for cystic fibrosis

Lightlake Therapeutics changes its name to Opiant Pharmaceuticals

FDA approves Harvoni for additional chronic HCV indications

Rosetta Genomics' thyroid cancer test approved in the state of New York

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...